000084357 001__ 84357
000084357 005__ 20200616135723.0
000084357 0247_ $$2doi$$a10.1177/1120672118804079
000084357 0248_ $$2sideral$$a110314
000084357 037__ $$aART-2018-110314
000084357 041__ $$aeng
000084357 100__ $$aAbreu-Gonzalez, R.
000084357 245__ $$aManagement of diabetic macular edema patients in clinical practice in Spain
000084357 260__ $$c2018
000084357 5060_ $$aAccess copy available to the general public$$fUnrestricted
000084357 5203_ $$aPurpose: Diabetic macular edema is the main cause of blindness in diabetic patients. Vascular endothelial growth factor is involved in diabetic macular edema pathogenesis. Vascular endothelial growth factor inhibitors are an important option in diabetic macular edema therapy. This survey investigates actual clinical practice in diabetic macular edema in Spain.
Methods: An expert advisory panel of 17 Spanish ophthalmologists developed a 30-item anonymous questionnaire about diagnosis, treatment, and follow-up in diabetic macular edema. A total of 137 ophthalmologists from 10 Spanish regions completed the questionnaire online.
Results: Almost all of the respondents (99.3%) record the measured visual acuity and perform biomicroscopic anterior (94.9%) and posterior (91.2%) segment examinations. Similarly, 100% of responding ophthalmologists always/almost always or frequently perform optical coherence tomography. Most respondents (65%) always/almost always or frequently perform a retinography. More than 50% rarely perform fluorescein angiography. Nearly, all (96.4%) of the specialists responded that, in center-involved diabetic macular edema, the first treatment is an anti–vascular endothelial growth factor drug. For corticosteroids, the first choice of most respondents (91.2%) was the dexamethasone implant. In the follow-up, almost all (96.4%) specialists record the measured visual acuity and most also perform biomicroscopic anterior (82.5%) and posterior (83.2%) segment examination.
Conclusion: This survey shows the actual clinical practice in diabetic macular edema in Spain, finding that anti–vascular endothelial growth factor therapy is frequently used, and that diagnosis, treatments, and follow-up examinations used by specialists are homogeneous and according to diabetic macular edema guidelines.
000084357 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000084357 590__ $$a1.716$$b2018
000084357 591__ $$aOPHTHALMOLOGY$$b32 / 59 = 0.542$$c2018$$dQ3$$eT2
000084357 592__ $$a0.614$$b2018
000084357 593__ $$aOphthalmology$$c2018$$dQ2
000084357 593__ $$aMedicine (miscellaneous)$$c2018$$dQ2
000084357 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000084357 700__ $$aGallego-Pinazo, R.
000084357 700__ $$aAbraldes, M.
000084357 700__ $$0(orcid)0000-0003-0349-9997$$aPinilla, I.$$uUniversidad de Zaragoza
000084357 700__ $$aLopez-Galvez, M.I.
000084357 7102_ $$11004$$2646$$aUniversidad de Zaragoza$$bDpto. Cirugía,Ginecol.Obstetr.$$cÁrea Oftalmología
000084357 773__ $$g29, 6 (2018), 1-9$$pEur. j. ophthalmol.$$tEuropean Journal of Ophthalmology$$x1120-6721
000084357 8564_ $$s138656$$uhttps://zaguan.unizar.es/record/84357/files/texto_completo.pdf$$yVersión publicada
000084357 8564_ $$s99207$$uhttps://zaguan.unizar.es/record/84357/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000084357 909CO $$ooai:zaguan.unizar.es:84357$$particulos$$pdriver
000084357 951__ $$a2020-06-16-13:50:51
000084357 980__ $$aARTICLE